233 related articles for article (PubMed ID: 22512587)
1. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.
Banerjee PS; Samanta S
Mini Rev Med Chem; 2013 Apr; 13(5):706-12. PubMed ID: 22512587
[TBL] [Abstract][Full Text] [Related]
2. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
4. Concise perspectives on some synthetic thiazolidine-2,4-dione derivatives and their specific pharmacodynamic aspects.
Vulichi SR; Kabra A; Kumar R; Suman K; Rao CV; Cruz-Martins N
Life Sci; 2021 Apr; 271():119182. PubMed ID: 33577851
[TBL] [Abstract][Full Text] [Related]
5. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
8. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
Sauer S
Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
[TBL] [Abstract][Full Text] [Related]
9. A Pharmacogenetic Approach to the Treatment of Patients With
Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
[TBL] [Abstract][Full Text] [Related]
10. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
11. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
12. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
Porskjær Christensen L; Bahij El-Houri R
Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
Chen Z; Vigueira PA; Chambers KT; Hall AM; Mitra MS; Qi N; McDonald WG; Colca JR; Kletzien RF; Finck BN
J Biol Chem; 2012 Jul; 287(28):23537-48. PubMed ID: 22621923
[TBL] [Abstract][Full Text] [Related]
14. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
16. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
Karak M; Bal NC; Bal C; Sharon A
Curr Diabetes Rev; 2013 Jul; 9(4):275-85. PubMed ID: 23746081
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW
Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579
[TBL] [Abstract][Full Text] [Related]
18. Rational drug design and PPAR agonists.
Perfetti R; D'Amico E
Curr Diab Rep; 2005 Oct; 5(5):340-5. PubMed ID: 16188168
[TBL] [Abstract][Full Text] [Related]
19. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
[TBL] [Abstract][Full Text] [Related]
20. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
